You have free access to this content

Cancer

Cover image for Cancer

15 May 2010

Volume 116, Issue 10

Pages 2287–2503

  1. CancerScope

    1. Top of page
    2. CancerScope
    3. Review Article
    4. Original Articles
    5. Communication
    6. Correspondence
    7. Errata
    1. You have free access to this content
    2. You have free access to this content
    3. You have free access to this content
  2. Review Article

    1. Top of page
    2. CancerScope
    3. Review Article
    4. Original Articles
    5. Communication
    6. Correspondence
    7. Errata
    1. You have free access to this content
      Central nervous system prophylaxis in adults with acute lymphoblastic leukemia : Current and emerging therapies (pages 2290–2300)

      Elias Jabbour, Deborah Thomas, Jorge Cortes, Hagop M. Kantarjian and Susan O'Brien

      Version of Record online: 5 MAR 2010 | DOI: 10.1002/cncr.25008

      • original image
      • original image

      Preventing central nervous system recurrence in adults with acute lymphoblastic leukemia remains problematic. This review indicated that several diagnostic modalities are available, but their optimal use still needs to be determined.

  3. Original Articles

    1. Top of page
    2. CancerScope
    3. Review Article
    4. Original Articles
    5. Communication
    6. Correspondence
    7. Errata
    1. Disease Site

      Breast Disease
      You have free access to this content
      A phase 2 study of a fixed combination of uracil and ftorafur and leucovorin given orally in a twice-daily regimen to treat patients with recurrent metastatic breast cancer (pages 2301–2306)

      Gabriel N. Hortobagyi, Robyn R. Young, Mark Karwal, Nuhad K. Ibrahim, Robert Hermann, James L. Murray, Stanley P. Watkins and Ira Gore Jr

      Version of Record online: 11 MAR 2010 | DOI: 10.1002/cncr.25042

      The combination of uracil and ftorafur (UFT) and leucovorin administered orally in a twice-daily regimen is reported to have modest activity in patients with metastatic breast cancer who had been previously treated with anthracyclines and/or taxanes. Grade 3 toxicities were found to be manageable with appropriate dose adjustments.

    2. You have free access to this content
      Excellent outcomes with adjuvant toremifene or tamoxifen in early stage breast cancer (pages 2307–2315)

      Jaime D. Lewis, Anees B. Chagpar, Elizabeth A. Shaughnessy, Jacob Nurko, Kelly McMasters and Michael J. Edwards

      Version of Record online: 5 MAR 2010 | DOI: 10.1002/cncr.24940

      • original image

      Women treated with adjuvant tamoxifen or toremifene for early stage breast cancer enjoy excellent outcomes. Because there are no significant differences with either medication, treatment of hormone receptor-positive patients with either tamoxifen or toremifene is appropriate.

    3. Genitourinary Disease
      You have free access to this content
      Trends in renal tumor surgery delivery within the United States (pages 2316–2321)

      Lori M. Dulabon, William T. Lowrance, Paul Russo and William C. Huang

      Version of Record online: 11 MAR 2010 | DOI: 10.1002/cncr.24965

      • original image

      Despite evidence of equivalent oncologic outcomes, analyses of population-based databases uniformly demonstrated the under use of partial nephrectomy and disparities in the care of patients with small renal tumors in the United States. This analysis of the most recent Surveillance, Epidemiology, and End Results database (1999-2006) indicated that significant discrepancies persist in the treatment practice patterns for older patients, women, and patients in rural settings.

    4. You have free access to this content
      Long-term neurologic and peripheral vascular toxicity after chemotherapy treatment of testicular cancer (pages 2322–2331)

      Jennifer L Glendenning, Yolanda Barbachano, Andy R. Norman, David P. Dearnaley, Alan Horwich and Robert A. Huddart

      Version of Record online: 11 MAR 2010 | DOI: 10.1002/cncr.24981

      • original image

      Peripheral neuropathy and Raynaud phenomenon persisted in approximately 20% of men and caused significant symptoms in 10% of patients who received chemotherapy for testicular cancer. Detectable effects on high-frequency thresholds also persisted but caused few ongoing, symptomatic problems.

    5. You have free access to this content
      Pretreatment assessment of tumor enhancement on contrast-enhanced computed tomography as a potential predictor of treatment outcome in metastatic renal cell carcinoma patients receiving antiangiogenic therapy (pages 2332–2342)

      Kyung Seok Han, Dae Chul Jung, Hyuck Jae Choi, Min Soo Jeong, Kang Su Cho, Jae Young Joung, Ho Kyung Seo, Kang Hyun Lee and Jinsoo Chung

      Version of Record online: 11 MAR 2010 | DOI: 10.1002/cncr.25019

      • original image
      • original image
      • original image
      • original image
      • original image

      Tumor enhancement on contrast-enhanced computed tomography (CECT) was associated with tumor size reduction, time to response, and time to progression of individual metastases in patients with metastatic renal cell carcinoma (mRCC) who received targeted therapy. The results from this study indicated that initial tumor enhancement on CECT may be useful as a clinical predictor during targeted therapy and to improve the selection of patients who may benefit from targeted therapy in the treatment of mRCC.

    6. Gynecologic Oncology
      You have free access to this content
      Invasive carcinoma of the uterine cervix associated with pregnancy : 90 years of experience (pages 2343–2349)

      B. Folke Pettersson, Sonia Andersson, Kristina Hellman and Ann-Cathrin Hellström

      Version of Record online: 5 MAR 2010 | DOI: 10.1002/cncr.24971

      • original image
      • original image
      • original image
      • original image

      In a retrospective study that included 219 cases of cervical cancer coincident with pregnancy, the authors observed that the incidence has declined, the disease is discovered at earlier stages, and survival has improved. In addition, the results indicated that pregnancy does not appear to influence the prognosis of women with cervical cancer.

    7. Head and Neck Disease
      You have free access to this content
      Association of p53 codon 72 polymorphism with risk of second primary malignancy in patients with squamous cell carcinoma of the head and neck (pages 2350–2359)

      Fanglin Li, Erich M. Sturgis, Xingming Chen, Mark E. Zafereo, Qingyi Wei and Guojun Li

      Version of Record online: 11 MAR 2010 | DOI: 10.1002/cncr.25072

      • original image

      p53 codon 72 polymorphism may modulate the risk of second primary malignancy in patients with squamous cell carcinoma of the head and neck, and this p53 polymorphism could be a risk marker for genetic susceptibility to second primary malignancy of patients with primary squamous cell carcinoma of the head and neck.

    8. Hematologic Malignancies
      You have free access to this content
      Alemtuzumab by continuous intravenous infusion followed by subcutaneous injection plus rituximab in the treatment of patients with chronic lymphocytic leukemia recurrence (pages 2360–2365)

      Stefan Faderl, Alessandra Ferrajoli, William Wierda, Susan O'Brien, Susan Lerner and Michael J. Keating

      Version of Record online: 11 MAR 2010 | DOI: 10.1002/cncr.24958

      • original image
      • original image

      Monoclonal antibodies may be used more effectively in combination. The combination of continuous intravenous infusion/subcutaneous alemtuzumab plus rituximab has a 53% response rate in patients with recurrent/refractory chronic lymphocytic leukemia with maximum response achieved after 1 cycle in most patients.

    9. You have free access to this content
      Characteristics of pericardial effusions in patients with leukemia (pages 2366–2371)

      Keeran Sampat, Adriana Rossi, Valentin Garcia-Gutierrez, Jorge Cortes, Sherry Pierce, Hagop Kantarjian and Guillermo Garcia-Manero

      Version of Record online: 5 MAR 2010 | DOI: 10.1002/cncr.24946

      • original image
      • original image
      • original image
      • original image

      Little is known in terms of the characteristics of pericardial effusions (PEs) in leukemia. Recently, it has been suggested that therapy with histone deacetylase inhibitors increases the incidence of PEs. Here the authors show that PEs are relatively common in leukemia, but are not related to specific types of therapy and have no impact on the survival of patients with leukemia.

    10. You have free access to this content
      Evaluation of the prognostic significance of Eosinophilia and Basophilia in a larger cohort of patients with myelodysplastic syndromes (pages 2372–2381)

      Friedrich Wimazal, Ulrich Germing, Michael Kundi, Thomas Noesslinger, Sabine Blum, Philipp Geissler, Christian Baumgartner, Michael Pfeilstoecker, Peter Valent and Wolfgang R. Sperr

      Version of Record online: 5 MAR 2010 | DOI: 10.1002/cncr.25036

      • original image
      • original image
      • original image
      • original image

      Although the prognostic significance of neutropenia and thrombocytopenia is well established in myelodysplastic syndromes, little is known about the prognostic impact of eosinophils and basophils. In the current study, the authors identified eosinophilia and basophilia as additional significant prognostic variables in myelodysplastic syndromes that may have implications for prognostication in daily clinical practice.

    11. Lung Disease
      You have free access to this content
      Phase 2 trial of pemetrexed disodium and carboplatin in previously untreated extensive-stage small cell lung cancer, N0423 (pages 2382–2389)

      Cheng E. Chee, James R. Jett, Albert M. Bernath Jr, Nathan R. Foster, Garth D. Nelson, Julian Molina, Daniel A. Nikcevich, Preston D. Steen, Patrick J. Flynn and Kendrith M. Rowland Jr

      Version of Record online: 5 MAR 2010 | DOI: 10.1002/cncr.24967

      • original image
      • original image

      In patients with untreated extensive-stage small-cell lung cancer, chemotherapy with pemetrexed plus carboplatin was well-tolerated even in elderly patients aged ≥70 years. However, this regimen was not as effective as standard therapy.

    12. You have free access to this content
      Varying recurrence rates and risk factors associated with different definitions of local recurrence in patients with surgically resected, stage I nonsmall cell lung cancer (pages 2390–2400)

      John M. Varlotto, Abram Recht, John C. Flickinger, Laura N. Medford-Davis, Anne-Marie Dyer and Malcolm M. DeCamp

      Version of Record online: 11 MAR 2010 | DOI: 10.1002/cncr.25047

      • original image
      • original image
      • original image
      • original image
      • original image
      • original image

      The current results indicted that recurrence rates and risk factors associated with local recurrence can vary in patients with surgically resected nonsmall cell lung cancer, depending on the definition of local recurrence. Comparable definitions must be used when analyzing different series.

    13. You have free access to this content
      Phase 2 study of carboplatin, docetaxel, and bevacizumab as frontline treatment for advanced nonsmall-cell lung cancer (pages 2401–2408)

      William N. William Jr, Merrill S. Kies, Frank V. Fossella, Diane D. Liu, Gregory Gladish, Warner H. Tse, J. Jack Lee, Waun K. Hong, Scott M. Lippman and Edward S. Kim

      Version of Record online: 11 MAR 2010 | DOI: 10.1002/cncr.24996

      • original image

      Carboplatin, docetaxel, and bevacizumab were feasible and effective for front-line treatments of advanced, nonsquamous, nonsmall-cell lung cancer. These data provide further evidence that bevacizumab may be used in combination with multiple standard platinum-based doublets in this setting.

    14. You have free access to this content
      Weekly alternating therapy with irinotecan plus cisplatin and etoposide plus cisplatin in the treatment of patients with extensive small cell lung carcinoma (pages 2409–2415)

      William N. William Jr, James Uyeki, Faye M. Johnson, Lei Feng, Beverly O. Peeples, Frank V. Fossella, Daniel D. Karp, George R. Blumenschein, David J. Stewart and Bonnie S. Glisson

      Version of Record online: 11 MAR 2010 | DOI: 10.1002/cncr.25076

      • original image

      This phase 2 trial estimated the efficacy of a treatment regimen in previously untreated patients with extensive small cell lung cancer. Weekly therapy with irinotecan/cisplatin alternating with etoposide/cisplatin was found to be well-tolerated in patients with extensive small cell lung cancer, but did not demonstrate improved progression-free or overall survival when compared with historical controls at the study institution.

    15. Melanoma
      You have free access to this content
      Does MC1R genotype convey information about melanoma risk beyond risk phenotypes? (pages 2416–2428)

      Peter A. Kanetsky, Saarene Panossian, David E. Elder, DuPont Guerry, Michael E. Ming, Lynn Schuchter and Timothy R. Rebbeck

      Version of Record online: 18 MAR 2010 | DOI: 10.1002/cncr.24994

      • original image

      Results from a case-control study and corresponding meta-analyses suggest that MC1R genotype provides information about melanoma risk beyond traditional risk factors, and that knowledge of MC1R genotype may be vital to melanoma risk prediction in persons with otherwise protective phenotypes.

    16. Sarcoma
      You have free access to this content
      Histology-specific nomogram for primary retroperitoneal soft tissue sarcoma (pages 2429–2436)

      Ilaria Ardoino, Rosalba Miceli, Mattia Berselli, Luigi Mariani, Elia Biganzoli, Marco Fiore, Paola Collini, Silvia Stacchiotti, Paolo Giovanni Casali and Alessandro Gronchi

      Version of Record online: 5 MAR 2010 | DOI: 10.1002/cncr.25057

      • original image
      • original image
      • original image
      • original image
      • original image

      This retroperitoneal sarcoma-specific nomogram enables the patient and physician to make more informed decisions regarding the possible indication of complementary treatments based on assessment of predicted risk for an individual patient rather than using traditional size cutpoints alone.

    17. Discipline

      Disparities Research
      You have free access to this content
      Do racial or socioeconomic disparities exist in lung cancer treatment? (pages 2437–2447)

      Relin Yang, Michael C. Cheung, Margaret M. Byrne, Youjie Huang, Dao Nguyen, Brian E. Lally and Leonidas G. Koniaris

      Version of Record online: 5 MAR 2010 | DOI: 10.1002/cncr.24986

      • original image
      • original image

      Lung cancer continues to carry a poor prognosis for all patients. Once comorbidities are corrected for, African American patients carry equivalently poor outcomes.

    18. Medical Oncology
      You have free access to this content
      Oxaliplatin and capecitabine in the treatment of patients with recurrent or refractory carcinoma of unknown primary site : A phase 2 trial of the Sarah Cannon Oncology Research Consortium (pages 2448–2454)

      John D. Hainsworth, David R. Spigel, Howard A. Burris III, Dianna Shipley, Cindy Farley, Ines M. Macias-Perez, John Barton and F. Anthony Greco

      Version of Record online: 5 MAR 2010 | DOI: 10.1002/cncr.25029

      • original image
      • original image

      Oxaliplatin-based regimens are routinely used in the treatment of gastrointestinal cancers, but to the authors' knowledge, their empiric use in carcinoma of an unknown primary site (CUP) has not been evaluated. In this multicenter, community-based phase 2 trial, the combination of oxaliplatin and capecitabine was found to have significant activity as a salvage treatment in patients with recurrent and refractory CUP and should be considered in patients with clinical and pathologic features suggesting a primary site in the gastrointestinal tract.

    19. You have free access to this content
      Medication errors involving oral chemotherapy (pages 2455–2464)

      Saul N. Weingart, Julio Toro, Justin Spencer, Deborah Duncombe, Anne Gross, Sylvia Bartel, Jeremy Miransky, Ann Partridge, Lawrence N. Shulman and Maureen Connor

      Version of Record online: 11 MAR 2010 | DOI: 10.1002/cncr.25027

      Oral chemotherapy medication errors often consist of the wrong dose, drug, or number of days of treatment supplied, or of missed doses. Incidents derived from a literature search and hospital incident reporting system yielded a higher percentage of injurious errors compared with pharmacy interventions, national reporting systems, and prompted clinician reports.

    20. Pediatric Oncology
      You have free access to this content
      A novel therapeutic combination for neuroblastoma : The vascular endothelial growth factor receptor/epidermal growth factor receptor/rearranged during transfection inhibitor vandetanib with 13-cis-retinoic acid (pages 2465–2475)

      Peter E. Zage, Lizhi Zeng, Shana Palla, Wendy Fang, Monique B. Nilsson, John V. Heymach and Patrick A. Zweidler-McKay

      Version of Record online: 11 MAR 2010 | DOI: 10.1002/cncr.25017

      • original image
      • original image
      • original image
      • original image
      • original image
      • original image
      • original image

      Children with high-risk and relapsed or refractory neuroblastoma have extremely poor outcomes, and have a critical need for new treatment options. The authors identified the rearranged during transfection (RET) tyrosine kinase as a potential therapeutic target in neuroblastoma cells and have demonstrated that the combination of RET inhibition with vandetanib and 13-cis-retinoic acid is effective against neuroblastoma tumor cells in in vitro and in vivo model systems.

    21. Radiation Oncology
      You have free access to this content
      High-dose proton therapy and carbon-ion therapy for stage I nonsmall cell lung cancer (pages 2476–2485)

      Hiromitsu Iwata, Masao Murakami, Yusuke Demizu, Daisuke Miyawaki, Kazuki Terashima, Yasue Niwa, Masayuki Mima, Takashi Akagi, Yoshio Hishikawa and Yuta Shibamoto

      Version of Record online: 11 MAR 2010 | DOI: 10.1002/cncr.24998

      • original image
      • original image
      • original image
      • original image

      The authors report 3-year results of particle therapy for stage I nonsmall cell lung cancer at the Hyogo Ion Beam Medical Center, which is the only facility in the world providing both proton and carbon-ion therapy. Despite inclusion of large T2 tumors, their results were comparable to published results of x-ray stereotactic radiotherapy, which is usually used to treat smaller tumors.

    22. You have free access to this content
      Pelvic radiotherapy and the risk of secondary leukemia and multiple myeloma (pages 2486–2492)

      Jason D. Wright, Caryn M. St. Clair, Israel Deutsch, William M. Burke, Prakash Gorrochurn, Xuming Sun and Thomas J. Herzog

      Version of Record online: 5 MAR 2010 | DOI: 10.1002/cncr.25067

      • original image
      • original image
      • original image
      • original image

      This study examined the risk of treatment-associated leukemia and multiple myeloma in patients treated with pelvic radiotherapy. Pelvic radiation is associated with an increased risk of secondary leukemia but does not appear to increase the risk of multiple myeloma.

  4. Communication

    1. Top of page
    2. CancerScope
    3. Review Article
    4. Original Articles
    5. Communication
    6. Correspondence
    7. Errata
    1. You have free access to this content
      A note from history : The First Printed Case Reports of Cancer (pages 2493–2498)

      Steven I. Hajdu

      Version of Record online: 11 MAR 2010 | DOI: 10.1002/cncr.25000

      • original image
      • original image
      • original image

      The case reports of cancer by Benivieni, Boneti, and Morgagni established the foundation for oncology.

  5. Correspondence

    1. Top of page
    2. CancerScope
    3. Review Article
    4. Original Articles
    5. Communication
    6. Correspondence
    7. Errata
    1. You have free access to this content
      Divergent cancer pathways for early onset and late onset cutaneous malignant melanoma : A role for sex-site interaction (page 2499)

      Beatriz Pérez-Gomez, Nuria Aragonés and Marina Pollan

      Version of Record online: 11 MAR 2010 | DOI: 10.1002/cncr.24985

      • original image

      Men and women with trunk melanoma have different age distributions. Age-specific rates in women suggest a possible role of female hormones in this location.

    2. You have free access to this content
    3. You have free access to this content
    4. You have free access to this content
  6. Errata

    1. Top of page
    2. CancerScope
    3. Review Article
    4. Original Articles
    5. Communication
    6. Correspondence
    7. Errata
    1. You have free access to this content
      Erratum: Pathogenesis of osteoblastic bone metastases from prostate cancer (page 2503)

      Toni Ibrahim, Emanuela Flamini, Laura Mercatali, Emanuele Sacanna, Patrizia Serra and Dino Amadori

      Version of Record online: 2 MAR 2010 | DOI: 10.1002/cncr.25132

      This article corrects:

      Pathogenesis of osteoblastic bone metastases from prostate cancer1

      Vol. 116, Issue 6, 1406–1418, Version of Record online: 27 JAN 2010

    2. You have free access to this content
      Erratum: Proposed adjustments to pathologic staging of epithelial malignant pleural mesothelioma based on analysis of 354 cases (page 2503)

      William G. Richards, John J. Godleski, Beow Y. Yeap, Joseph M. Corson, Lucian R. Chirieac, Lambros Zellos, Aneil Mujoomdar, Michael T. Jaklitsch, Raphael Bueno and David J. Sugarbaker

      Version of Record online: 11 MAR 2010 | DOI: 10.1002/cncr.25131

      This article corrects:
    3. You have free access to this content
      Erratum: Progress for resectable cancer?: A population-based assessment of US practices (page 2503)

      Jessica P. Simons, Sing Chau Ng, Theodore P. McDade, Zheng Zhou, Craig C. Earle and Jennifer F. Tseng

      Version of Record online: 24 FEB 2010 | DOI: 10.1002/cncr.25133

      This article corrects:

      Progress for resectable cancer?

      Vol. 116, Issue 7, 1681–1690, Version of Record online: 8 FEB 2010

SEARCH

SEARCH BY CITATION